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ABSTRACT
Objective: To describe real-life practice and person-
centred outcomes in the treatment of poststroke upper
limb spasticity with botulinum toxin A (BoNT-A).
Design: Observational, prospective study.
Setting: 84 secondary care centres in 22 countries.
Participants: 456 adults (≥18 years) with poststroke
upper limb spasticity treated with one cycle of BoNT-A.
Methods/outcomes: Muscle selection, BoNT-A
preparation, injection technique and timing of follow-up
were conducted according to routine practice for each
centre. Primary outcome: achievement of the patient’s
primary goal for treatment using goal-attainment scaling
(GAS). Measurements of spasticity, standardised outcome
measures and global benefits were also recorded.
Results: The median number of injected muscles was 5
(range 1–15) and the most frequently injected muscles
were the long finger flexors, followed by biceps and
brachioradialis. The median (range) follow-up time was
14 (2.6 to 32.3) weeks. The common primary treatment
goals were passive function (132 (28.9%)), active
function (104 (22.8%)), pain (61 (13.4%)), impairment
(105 (23%)), involuntary movement (41 (9%)) and
mobility (10 (2.2%)). Overall, 363 (79.6%) (95% CI
75.6% to 83.2%) patients achieved (or overachieved) their
primary goal and 355 (75.4%) (95% CI 71.2% to 79.2%)
achieved their secondary goal. Mean (SD) change from
baseline in GAS T-scores was 17.6 (11.0) (95% CI 16.4
to 18.8; p<0.001). GAS T-scores were strongly correlated
with global benefit and other standard measures
(correlations of 0.38 and 0.63, respectively; p<0.001).
Conclusions: BoNT-A demonstrated a clinically
significant effect on goal attainment for the real-life
management of upper-limb spasticity following stroke. The
study confirms the feasibility of a common international
data set to collect systematic prospective data, and of
using GAS to capture person-centred outcomes relating to
passive and active functions and to pain.
Registration ClinicalTrials.gov identifier: NCT01020500
ARTICLE SUMMARY
Article focus
▪ A large international observational cohort study
(the Upper Limb International Spasticity
(ULIS)-II) to describe the use of botulinum toxin
A (BoNT-A) for management of upper-limb spas-
ticity in the context of real-life clinical practice.
▪ To quantify and characterise the achievement of
person centred goals following one BoNT-A
injection cycle delivered in the context of routine
clinical practice.
▪ To describe the variations in clinical practice and
explore prognostic factors that may impact on
outcome.
Key messages
▪ Despite wide variations in the approach to clin-
ical practice, a large majority (80%) of the
patients achieved their treatment goals, mainly in
terms of passive and active functions and pain
reduction.
▪ The results provide evidence that BoNT-A injec-
tions may contribute to an improvement in the
daily life of patients and their carers beyond
simple improvement of tone or spasticity.
Strengths and limitations of this study
▪ The wide geographical distribution of centres
across three continents is a strength of this
study, but recruitment of only 5–12 patients/site
may not adequately reflect the patient population
of each centre.
▪ The study lays the foundation for larger inter-
national longitudinal cohort studies to explore
further the characteristics and treatment
approaches that predict best outcomes in
BoNT-A treatment of upper limb spasticity.
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INTRODUCTION
Spasticity is a common and distressing sequela of stroke,
which interferes with upper limb movement and limits
the use of the limb for active functional tasks, as well as
impacting on mobility and increasing the burden on
caregivers.1
From controlled clinical trials conducted to date,2–9 it
is established that botulinum toxin A (BoNT-A) is safe
and effective in reducing spasticity. However, functional
gains have been harder to demonstrate,10 especially as
there is wide diversity in the pattern of spasticity and
goals for treatment leading to individual variations in
response. We also know that clinicians vary in their
approach to treatment with respect to selection of
muscle, injection technique and follow-up therapy.
These variations appear to have more to do with clin-
ician bias and local availability of services than with
patient presentation.12
It is now time to extend the ﬁeld of investigation in
this area to understand how BoNT-A is used in routine
clinical practice around the world and gain better
understanding of how to select patients most likely to
respond to treatment. Establishing what treatment
approaches work best based on clinical presentation
would also be of great clinical value. To do this, we will
need to build a consistent body of data that captures
clinically important change at an individual level and is
of sufﬁcient size and generalisability to enable us to
answer these critical questions.
The Upper Limb International Spasticity (ULIS) pro-
gramme consists of a series of large international obser-
vational studies to describe current clinical practice in
the application of BoNT-A in this context, and to work
towards the development of a common international
data set for prospective systematic recording of longitu-
dinal outcomes.13 Importantly, the programme incorpo-
rates elements of a) training in the use of agreed
outcome measures, and b) development of electronic
data-collection tools suitable for use by the wider inter-
national community.
Goal-attainment scaling (GAS) was chosen as the
primary person-centred outcome measure to capture
the diversity of treatment intentions that are important
to the individual patient and their family/carers. First
described by Kiresuk and Sherman14 in the 1960s, GAS
is increasingly used in the context of spasticity manage-
ment15 16 and is shown to be sensitive to changes follow-
ing focal intervention that are not detected by more
global measures.11 Although GAS provides a useful
measure of achievement of treatment intention, it does
not measure outcome per se, and therefore does not
stand alone but is used alongside other standardised
outcome measures.17 It is therefore pertinent to under-
stand the relationship between GAS and other outcome
tools.
This second stage in the ULIS programme (ULIS-II) is
a large international observational cohort study to
describe the real-life practice and outcomes in the
treatment of poststroke upper limb spasticity with
BoNT-A. This is the ﬁrst large international cohort study
to use GAS as a primary outcome measure for the
person-centred evaluation of treatment with BoNT-A for
spasticity. In a separate paper, we have presented the
rationale and methodology for ULIS-II in detail, and
described the steps taken to ensure the validity of GAS
as a measure of functional gains in this context.13 In this
study, we describe the baseline clinical characteristics,
details of interventions and the primary results in
accordance with the STROBE guidelines for presenta-
tion of cohort studies.18
AIMS AND OBJECTIVES
The primary objective of the ULIS-II study was to assess
the responder rate (as deﬁned by the achievement of
the primary goal from GAS) following one BoNT-A
injection cycle delivered in the context of routine clin-
ical practice.
Secondary objectives were to
▸ Describe the baseline characteristics, including demo-
graphics, duration and pattern of spasticity, concomi-
tant therapies/medication, etc;
▸ Describe injection practices (muscle identiﬁcation,
dosage, dilution, etc);
▸ Assess achievement of secondary goals and evaluate
the overall attainment of treatment goals using the
GAS T-score as a patient-centred measure of
outcome;
▸ Document the use of standardised outcome measures
and their results;
▸ Assess the global beneﬁts as perceived by the investi-
gator and the patient.
Additional exploratory objectives, addressed through
the analysis plan, were to
▸ Describe the common goal areas for treatment and
to identify those in which goals were most often
achieved;
▸ Examine the relationship between GAS and other
standardised outcome measures;
▸ Identify any prognostic factors for response.
METHODS
Full details of the methodology are described else-
where.13 In brief, ULIS-II was an 18-month, postmarket-
ing, international, multicentre, observational,
prospective, before-and-after study, conducted in 84
centres in 22 countries spanning Europe, Paciﬁc Asia
and South America.
The study was conducted in compliance with
Guidelines for Good Pharmacoepidemiology Practices.
Marketing authorisation for the use of BoNT-A in this
context was ensured for each participating country prior
to the start of the study. Ethical approval and written
informed consent to the recording of anonymous data
were obtained in countries where this was required.
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Recruitment took place between January 2010 and
May 2011. To limit the potential bias from over-
recruiting sites, the number of patients was limited to 5–
12 patients/treatment centre. All centres recruited at
least ﬁve patients, but 25 of the more experienced
centres (which were usually also larger) could recruit up
to 12 patients. This was allowed to try to ensure a repre-
sentative sample from clinicians with experience in this
area of practice. It also offers an opportunity for future
subanalysis of the differences between experienced and
less experienced injectors.
Centres included consecutive patients—or spaced
inclusions in a predeﬁned manner (eg, one for every 2–
3 patients) if necessary for pragmatic reasons—until
their recruitment target was achieved.
Study population
The main inclusion criteria required patients to be con-
senting adults ≥18 years with poststroke upper limb spas-
ticity in whom a decision had already been made to
inject BoNT-A, and who had had no previous treatment
with BoNT-A or BoNT-B within the last 12-weeks.
Agreement on an achievable goal set and ability to
comply with the prescribed treatment were also
required. The efﬁcacy population analysed here
included all participants who received one BoNT-A
injection and who underwent a postinjection visit includ-
ing an assessment of GAS.
Study schedule
Baseline evaluation at Time 1 included
▸ Demography and history of the stroke including type,
location and time since onset.
▸ The pattern of impairment in the affected upper
limb (modiﬁed Neurological Impairment Scale).19 20
▸ Previous/concomitant treatments for upper limb
spasticity.
▸ Clinical examination, including measurements of
spasticity and other standardised outcome measures
as routinely performed in that centre.
▸ Goal setting and GAS applied using the ‘GAS-light’
method,21 as detailed in the rationale and method-
ology paper,13 with emphasis on setting SMART (spe-
ciﬁc, measurable, achievable, realistic and timed)
function-related goals agreed on between the investi-
gator, the patient and the treating team.
▸ One primary and up to three secondary goals were
set and assigned to one of seven goal categories.
Injection of BoNT-A
To reﬂect real-life practice in this observational study,
physicians were free to choose targeted muscles, BoNT-A
preparation, injected doses, number of points and
volume for each point and use of EMG/electrical stimu-
lation in accordance with their usual practice, and with
their local Summary of Product Characteristics and
therapeutic guidelines. The timing of follow-up was at
the discretion of the investigator, based on their usual
practice and the nature of the goals set, usually between
months 3 and 5.
Follow-up evaluation at Time 2 included
▸ Achievement of primary and secondary GAS goals
rated on a six-point verbal rating scale, and tran-
scribed within the computer software to the ﬁve-point
numerical scale (range −2 to +2), and the GAS
T-score.
▸ Any concomitant treatments for upper limb spasticity
given since baseline.
▸ Clinical examination including measurements of spas-
ticity as normally routinely performed.
▸ Global assessments of beneﬁts were rated by the
investigator and patient as: ‘great beneﬁt (+2)’, ‘some
beneﬁt (+1)’, ‘same (0)’, ‘worse (−1)’ or ‘much
worse (−2)’.
▸ Change on any standardised measures performed was
recorded on the same ﬁve-point scale.
▸ The next therapeutic strategy—including any
planned re-injection with BoNT-A—whether using
the same agent and protocol or an adjusted one.
As this was an observational study, reporting of related
adverse events followed the standard regulations related
to spontaneous adverse event reporting for marketed
products.
Study size
The sample size calculation was based on an estimate
that 60% of patients would achieve their primary goal
following their ﬁrst BoNT-A injection cycle. Using a 5%
two-sided signiﬁcance level, with a power of 80%, 450
patients were needed to allow estimation of this propor-
tion with a precision of 4.5%. This sample size also
allowed the detection of potential prognostic factors to
response (based on the detection of odd ratio (OR)
larger than or equal to 2).
Statistical analysis
Data were entered by the treating clinicians into an elec-
tronic case report form (eCRF). After cleaning and val-
idation of the data set, statistical evaluations were
performed using Statistical Analysis System (V.9).
Analyses were conducted on the efﬁcacy population.
For the primary statistical analysis, ‘Responders’ were
those who achieved their primary goal (GAS score 0, 1
or 2).
▸ Baseline characteristics and efﬁcacy evaluations are
presented as descriptive statistics, including 95% CI
where relevant.
▸ Mean and SD are reported for interval quality data,
including long-ordinal data that fulﬁlled the criteria
for normal distribution (eg, Modiﬁed Ashworth Scale
(MAS) total and GAS T-scores).
▸ 95% CI for percentage were calculated as p±1.96×SE.
SEs were calculated as √(pq/n), where p is the rate,
q=1–rate and n=sample size.
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▸ Short ordinal data are described by median and IQR
and analysed using non-parametric statistical
techniques.
As originally described by Kiresuk and Sherman, the
GAS T-score provides a composite score (the sum of the
attainment levels×the relative weights (optional) for
each goal) transformed into a standardised measure
with a mean of 50 and an SD of 10. Several different
scoring methods are currently used in the literature to
account for partial achievement of goals in GAS.22 In
this study, baseline scores were rated as −1=‘some func-
tion’ and −2=‘no function’ with respect to the goal.
T-scores were calculated with weighting (importance),
and partial achievement was rated as −1 to conserve the
normal distribution of scores.22
MAS scores were recorded for the shoulder, elbow,
wrist, ﬁngers and thumb joints. Scores of ‘1+’ were
entered as 1.5 in the calculation of the total MAS score
and combined to composite scores as follows:
MAS-Proximal=shoulder+elbow scores; MAS-Distal=wrist
+ﬁngers+thumb scores; MAS-total=composite sum of all
ﬁve joints.
Relationships between GAS T-scores and other mea-
sures of outcome (eg, measures of spasticity, global
beneﬁt and other standardised measures) were exam-
ined using Spearman’s rank correlation coefﬁcients.
Stepwise logistic regression modelling was used to
identify prognostic factors for achievement of the
primary goal. Potential covariates included stroke aeti-
ology, primary goal area, duration and severity of spasti-
city, time interval to follow-up, presence of confounding
factors (including the presence of contractures;
impaired motor, sensory, cognitive, emotional and cor-
tical function (ie, neglect, dyspraxia, visuospatial deﬁcits,
etc). A backward elimination analysis was followed using
a signiﬁcance level of 0.2 to retain variables in the
model. The Hosmer and Lemeshow goodness-of-ﬁt
test18 was used and 95% CI for OR estimated by the
logistic model was calculated.
RESULTS
Recruitment and participation
A total of 468 participants were enrolled in this study of
which 12 were excluded from the efﬁcacy population
(n=456). Eleven participants were excluded because
they did not attend their follow-up visit for assessment of
GAS (n=5 lost to follow-up, n=3 subject death unrelated
to study medication and n=3 for other reasons). An add-
itional participant was excluded as treatment was given
in the lower (rather than the upper) limb. No partici-
pants withdrew because of withdrawal of consent, lack of
efﬁcacy or adverse effect related to the BoNT-A
treatment.
Demographics and disease characteristics
The geographic distribution and demographics of the
efﬁcacy population are described in detail elsewhere.13
The mean (SD) age was 57 (13.5) years and mean (SD)
time since onset of stroke was 61.4 (69.1) months.
Fifty-eight per cent of the population was men; 70% had
had infarcts and 30% had haemorrhagic stroke. Left
and right hemisphere localisation was approximately
equal (47.1 : 51.1%, respectively) and 3% had posterior
circulation strokes.
Baseline characteristics are detailed in table 1. Distal
patterns of spasticity predominated. A quarter had evi-
dence of soft tissue shortening and more than half had
severe motor weakness. Over half of the participants
(57%) had no useful hand function and 46% had
sensory impairment. These ﬁndings conﬁrm that the
majority of participants had chronic spasticity with
severe impairment and therefore little potential for
recovery of useful motor function. In contrast, the cogni-
tive and communication impairments were relatively
uncommon and were mostly mild in nature.
BoNT-A injection history
Approximately two-thirds of the participants (n=307;
67.3%) had received a previous injection of BoNT-A in
the upper limb. The mean (SD) time since the last
injection was 8.0 (11.5) months and the median time
was 5 months (IQR 3–5, range 1–102 months). Some
had had treatment spanning several years.
The median time since the ﬁrst injection was
24 months (range 3–168 months), but two-thirds of the
participants had had BoNT-A treatment for over 1 year.
The median number of BoNT-A injections previously
received by the participants was 4 (IQR 1–8; range 1–45).
BoNT-A treatment
In this cohort, abobotulinumtoxinA (Dysport) was
the most commonly used agent (70.4%), followed by
onabotulinumtoxinA (Botox; 21.5%) and
incobotulinumtoxinA (Xeomin; 7.7%); two patients
received another local BoNT-A preparation. The median
number of injected muscles was 5.0 (range 1–15). There
was very wide variation in the total dose of BoNT-A (see
table 2).
The most commonly injected muscles and doses, by
treatment, are shown in table 3. The most frequently
injected were the long-ﬁnger ﬂexors, followed by biceps
and brachioradialis. With the exception of the pectoralis
major (which was injected in 19.3% of patients), the
shoulder muscles were relatively rarely injected. Multiple
injection points were most commonly used in the larger
and more proximal muscles, such as the biceps and the
pectoralis major. Electrical stimulation was more com-
monly used to locate muscles than EMG (45.8% vs
29.2%), especially for the smaller muscles such as the
ﬂexor pollicis longus.
At Visit 2, the median (range) follow-up time was 14
(2.6–32.3) weeks, and further injection was planned in
361 (79.2%) participants. Clinicians planned to inject
the same muscles in 254 (70.4%) with the same dose in
227 (62.9%). In 134 (37.1%), a different dose was
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planned (increased in 26.3% and decreased in 10.8%),
but only 10 (2.8%) planned to use a different agent.
Concomitant treatments
Nearly two-thirds (61.6%) of the patients were receiving
physiotherapy in association with the BoNT-A treatment
at follow-up, and over a third (39.5%) of participants
also received occupational therapy. However, there was
wide variation in the number of sessions received (see
table 4).
The types of concomitant treatments at baseline and
follow-up are shown in table 4. At baseline, the fre-
quency of concomitant treatments ranged from 18%
(functional electrical stimulation) to 93% (passive
stretching). By follow-up, the overall frequency of con-
comitant therapies had diminished, although the range
of modalities remained similar. Notably, the proportion
of patients on antispasmodic medication fell from 46%
to 28.5%.
Primary and secondary goal areas
Primary and secondary goal areas set at baseline are
shown in table 5. Goals were most commonly set in the
areas of passive function, impairment and active func-
tion followed by pain, and involuntary movement. Less
commonly in this data set, goals focused on mobility (ie,
Table 1 Baseline clinical characteristics of the efficacy population
Parameter Values (%) Range n/missing or untestable
Distribution of spasticity (MAS ≥2), n (%)
Shoulder 235 (55.7) 422/34
Elbow 335 (75.1) 446/10
Wrist 344 (77.8) 442/14
Fingers 368 (82.9) 444/12
Thumb 292 (66.8) 437/19
Soft tissue shortening (limiting ≥half range), n (%) 456/0
Shoulder 156 (34.2)
Elbow 150 (32.9)
Wrist 179 (39.3)
Hand 206 (45.2)
Motor paralysis (no useful function), n (%) 456
Proximal 95 (20.8)
Distal 260 (57.0)
Sensory, n (%) 447/9
Partial 208 (45.6)
Complete 20 (4.4)
Cognitive/communicative impairment, n (%)
Cognitive 98 (21.5) 455/1
Speech and language 159 (34.9) 446/10
Neglect, dyspraxia or visuo-perceptual difficulties 60 (13.2) 456/0
Other symptoms, which may impact on functional outcome, n (%) 456/0
Emotional/behavioural impairment 149 (32.7)
Pain* 78 (17.1)
Fatigue 48 (10.5)
Impairment scores (modified NIS) † Median (Q1–Q3) Range n/untestable
Proximal upper limb motor score (arm raising/reaching) 2 (1–2) 0–3 456/0
Distal upper limb motor score (hand function) 3 (2–3) 0–3 456/0
Sensation 1 (0–2) 0–3 447/9
Communication impairment 0 (0–1) 0–3 455/1
Cognitive impairment 0 (0–0) 0–3 446/10
Spasticity (MAS)‡ n/missing
Distal composite MAS score 7.0 (6–9) 0–12 431/25
Proximal composite MAS score 4.0 (3–5) 0–8 422/34
Baseline outcome measures
Total MAS score, mean (SD) 11.0 (3.3) 1–20 414/42
GAS weighted score, mean (SD) 36.4 (7.7) 21.2–43.8 456/0
As multiple answers were possible, the sum of some percentages in this table may exceed 100%.
*Data extracted from injected segments at baseline, when at least one muscle of the segment was injected.
†Modified NIS: the score range for each of the five domains is 0=none; 1=mild impairment affecting high-level function only; 2=significant
impairment; 3=severe impairment, effectively preventing function. Further details are available from the corresponding author.
‡MAS composite scores: proximal MAS score=shoulder+elbow scores; MAS-distal=wrist+fingers+thumb scores; MAS-total=composite sum
of all five joints (total composite scores were only calculated if individual MAS scores were recorded at all five joints).
MAS, Modified Ashworth Scale; NIS, Neurological Impairment Scale.
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improvement in balance or gait quality by restoring
freedom of upper limb movement) or other areas, such
as cosmesis or supporting therapy interventions.
Overall, 363 (79.6%; 95% CI 75.6 to 83.2) patients
achieved (or overachieved) their primary goal with 355
(75.4%; 95% CI 71.2% to 79.2%) achieving their sec-
ondary goal (see table 5). Although the rate of achieve-
ment was lower (but not statistically signiﬁcant) for
active function goals in comparison with passive function
and impairment goals, in this series, a total of 182
(primary and secondary) goals were set in relation to
active function of which 122 (67%) were achieved,
either as expected (73 (40.1%)) or beyond expectation
(49 (26.9%)). Pain reduction was a goal for treatment in
nearly one-third of the patients (145 (31.8%)), and was
achieved in 83.5%.
Secondary outcomes
At follow-up, the mean (SD) weighted GAS T-score was
52.0 (10.1; median 50.0, IQR 13.8), giving a mean (SD)
change from baseline of 17.6 (11.0; 95% CI 16.6 to 18.6;
p<0.001). Baseline and mean change from baseline in
GAS T-scores were similar between BoNT-A
preparations.
The mean (SD) MAS total score at follow-up was 8.4
(3.4), giving a mean (SD) change from baseline of −2.6
(2.6; 95% CI −2.9 to −2.4; p<0.0001). Overall, 90.1% of
investigators and 85.8% of patients considered BoNT-A
treatment to be of beneﬁt.
GAS T-scores correlated, albeit rather weakly, with a
reduction in total MAS at follow-up (Spearman r 0.28;
p<0.0001). They correlated more strongly, however, with
global assessment of beneﬁt (Spearman r 0.38; p<0.0001
for investigator assessment and 0.45; p<0.0001 for
patient assessment).
Standardised measures of upper limb spasticity
Reﬂecting common impairment, the ranges of active
(56.1%) and passive (54.4%) motion were the most
commonly recorded standardised measures of upper
limb spasticity used at baseline (table 6). Approximately
one-third (34.4%) of the patients also used a visual ana-
logue rating to reﬂect symptoms such as pain or carer
burden. However, only a very small minority (7.2%) had
a standardised measure of functional outcome recorded,
such as the Arm Activity Scale (ArMA—a self-report
measure of active and passive functions; 5.9%) or the
Leeds Adult Spasticity Impact Scale (LASIS—an
investigator-reported measure of passive function; 1.3%).
As shown in table 6, the GAS T-score correlated strongly
with a change in these standardised measures wherever
they were measured.
Identification of potential prognostic factors
Potential predictors with a p<0.20 were the primary goal
area, primary goal score at baseline, ﬁrst administration
of BoNT-A and cortical function. These were entered
into the multivariate logistic model. Results indicated
that patients with impaired cortical function were half as
likely to respond to treatment (OR 0.48 (95% CI 0.26 to
0.89)). The most likely explanation for this is that
patients with dyspraxia, neglect or poor visuospatial per-
ception are more likely to have difﬁculty complying with
and carrying through any treatment programme.
A non-signiﬁcant trend was also seen for poorer goal
achievement in patients receiving their ﬁrst administra-
tion of BoNT-A, compared with those who had had pre-
vious injections (OR 0.69 (95% CI 0.43 to 1.12)).
Possible explanations for this may be that dose-ranging
and muscle selection had been optimised through previ-
ous injections, or that patients beneﬁted from their
prior experience to better deﬁne their treatment goals.
DISCUSSION
The ﬁndings from this large prospective international
cohort study showed good response rates overall to
BoNT-A injection delivered in the context of routine
clinical practice for the management of upper limb spas-
ticity. The study demonstrated wide variation in clinical
practice with respect to the selection of muscles and
approach to injection, highlighting the need for further
systematic research into which approaches are likely to
Table 2 BoNT-A treatment
Current injection
Agent*
Dysport
n=321 (70.4%)
Botox
n=98 (21.5%)
Xeomin
n=35 (7.7%)
No. of injected muscles
Median (IQR) 5 (2) 5 (2) 5 (2)
Range 1–11 1–15 3–9
Dose
Total dose range (units) 40–1900 50–500 100–600
Localisation of injection (used for at least one muscle), n (%)
EMG 91 (28.3) 34 (34.7) 6 (17.1)
Electrical stimulation 145 (45.2) 53 (54.1) 9 (25.7)
*Two participants received other BoNT-A preparations.
BoNT-A, botulinum toxin A; EMG, electromyography.
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Table 3 Most commonly injected muscles and technique within each upper limb segment
Group/muscle Total number
injected (%)*
Number of units: median (IQR) Range of units (min, max) Multiple
points (%)
Use of
EMG (%)
Electrical
stimulation (%)Dysport Dysport Botox Xeomin Dysport Botox Xeomin
Shoulder n=147 (32.2)
Pectoralis major 88 (19.3) 200.0 (150.0) 30.0 (40.0) 70.0 (30.0) 30, 750 10, 100 20, 140 55 (62.5) 11 (12.5) 25 (28.4)
Teres major 17 (3.7) 75.0 (50.0) 10.0 (10.0) 50.0 (60.0) 50, 200 10, 50 40, 100 2 (11.8) 8 (47.1) 8 (47.1)
Deltoideus 15 (3.3) 100.0 (100.0) 50.0 (0.0) N/A 50, 300 50, 50 N/A 1 (6.7) 3 (20.0) 7 (46.7)
Subscapularis 14 (3.1) 200.0 (100.0) 30.0 (0.0) 50.0 (0.0) 75, 320 20, 40 50, 50 3 (21.4) 1 (7.1) 11 (78.6)
Latissimus dorsi 9 (2.0) 120.0 (125.0) 55.0 (90.0) 40.0 (0.0) 75, 200 10, 100 40, 40 6 (66.7) 4 (44.4) 2 (22.2)
Upper arm n=336 (73.7)
Biceps brachii 270 (59.2) 200.0 (150.0) 50.0 (10.0) 55.0 (40.0) 50, 750 20, 100 20, 100 208 (77.0) 52 (19.3) 70 (25.9)
Brachialis 130 (28.5) 150.0 (100.0) 50.0 (20.0) 60.0 (27.5) 20, 400 10, 100 30, 80 76 (58.5) 30 (23.1) 62 (47.7)
Triceps brachii 18 (3.9) 175.0 (100.0) 30.0 (25.0) N/A 60, 300 20, 100 N/A 15 (83.3) 8 (44.4) 8 (44.4)
Lower arm n=434 (95.2)
Flexor digit. superficialis 325 (71.3) 150.0 (100.0) 50.0 (35.0) 60.0 (37.5) 20, 500 15, 150 30, 100 195 (60.0) 91 (28.0) 151 (46.5)
Flexor digit. profondus 265 (58.1) 150.0 (100.0) 50.0 (30.0) 50.0 (20.0) 50, 600 15, 150 20, 200 142 (53.6) 66 (24.9) 114 (43.0)
Flexor carpi radialis 262 (57.5) 125.0 (100.0) 33.3 (25.0) 45.0 (40.0) 20, 350 5, 100 20, 80 83 (31.7) 73 (27.9) 99 (37.8)
Brachioradialis 156 (34.2) 112.5 (100.0) 40.0 (35.0) 50.0 (20.0) 25, 300 10, 75 20, 75 55 (35.3) 29 (18.6) 46 (29.5)
Pronator teres 138 (30.3) 100.0 (75.0) 40.0 (25.0) 40.0 (30.0) 25, 500 10, 100 10, 50 44 (31.9) 26 (18.8) 53 (38.4)
Flexor pollicis longus 136 (29.8) 100.0 (50.0) 25.0 (12.5) 35.0 (30.0) 20, 250 5, 50 10, 60 29 (21.3) 31 (22.8) 79 (58.1)
Hand/fingers n=204 (44.7)
Flexor pollicis brevis 47 (10.3) 50.0 (50.0) 15.0 (12.5) 20.0 (0.0) 10, 200 5, 30 20, 40 7 (14.9) 6 (12.8) 19 (40.4)
Adductor pollicis 37 (8.1) 50.0 (22.5) 25.0 (15.0) 20.0 (20.0) 20, 125 10, 30 10, 30 0 8 (21.6) 10 (27.0)
Lumbricales 32 (7.0) 100.0 (120.0) 25.0 (10.0) 40.0 (47.5) 50, 400 15, 40 20, 75 29 (90.6) 8 (25.0) 11 (34.4)
Interossei dorsales 22 (4.8) 150.0 (150.0) 25.0 (30.0) N/A 50, 375 10, 80 N/A 20 (90.9) 6 (27.3) 9 (40.9)
Opponens pollicis 18 (3.9) 50.0 (50.0) 30.0 (20.0) 5.0 (0.0) 10, 120 20, 40 5, 5 0 3 (16.7) 9 (50.0)
Percentages are based on the number of participants injected in the muscle, except * for which percentages are based on the number of participants in the efficacy population.
EMG, electromyography; IQR, interquartile range.
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be most effective for which patients. Nevertheless,
almost 80% of patients achieved their primary goal, as
deﬁned by the patients—together with their clinical
team—at the start of treatment. The study also conﬁrms
the feasibility of collecting data across a large inter-
national community, using an eCRF.
Patient-reported outcomes are increasingly recognised
as important indicators of quality of daily life for patients
and/or their carers, and in this study GAS was selected
as the primary endpoint in order to evaluate the bene-
ﬁts of treatment in terms of the attainment of individual
person-centred goals. It also provides important insight
into the nature of goals that are chosen as priorities for
treatment, and also those that are most likely to be
achieved.
In keeping with ﬁndings from other studies,11 25
improvement in passive function was the most frequently
selected primary goal area for treatment (29%), and
primary goals in this area were achieved in around 86%
of cases. Goals for active function were also commonly
set in nearly a quarter of the patients (22%). Perhaps
unsurprisingly in this population with chronic spasticity
and severe motor impairment, the achievement rate was
somewhat lower for active function. Nevertheless, 72%
of patients achieved their primary active function goal.
The second most commonly achieved primary goal area
was pain (set in 13% of patients), where again achieve-
ment was around 84%. Functional goals relating to invol-
untary movements and mobility were less commonly set
in this population but were nevertheless achieved at
broadly similar rates overall. The wide diversity in treat-
ment goals between patients, however, highlights the
importance of deﬁning the primary treatment intentions
clearly and then evaluating outcome speciﬁcally in rela-
tion to those.
Over and above the achievement of the primary goal,
the GAS T-score provides an overall assimilation of
attainment of primary and secondary goals regardless of
the number of goals set. Some authors have cast doubt
on the value of calculating a GAS T-score.26 In this study,
we went to considerable lengths to ensure that GAS was
applied rigorously and goals were focused on functional
gains,13 so it is worth reﬂecting on the added value of
the GAS T-score in this context.
▸ If goals are set in an unbiased fashion, and are
neither overambitious or overcautious, the mean GAS
T-score should be around 50 (±SD 10).21 Our mean
(SD) GAS T-score at follow-up of 52 (10.1) provides a
useful quality check of the team’s ability to set and
negotiate achievable goals, neither overestimating nor
underestimating the expected outcome.
▸ Previous authors have recorded that GAS change
scores >10 represent clinically meaningful
change.11 17 21 In this study, the mean improvement
in the GAS T-score from baseline to follow-up was
17.6. This conﬁrms the ﬁndings from one RCT,16 and
provides supportive evidence that BoNT-A produces
clinically meaningful change at a functional level in
the treatment of spasticity in real life practice.
▸ Importantly, GAS T-scores provide a single numerical
evaluation of overall goal achievement for compari-
son with other outcome measures. If the gains occur
as a result of reduction in spasticity, some correlation
with change in the MAS score would be expected,
even though the relationship may not necessarily be
very strong11 16 and indeed this was found. The sig-
niﬁcant correlations with other standardised mea-
sures (especially the Arm Activity Scale) provide
further support for GAS as a meaningful person-
centred measure of outcome in this context.
The ﬁndings of this study also give insight into the
longer term treatment of upper limb spasticity. Many of
the patients enrolled in this study had received several
previous BoNT-A injections, often over several years, sug-
gesting that patients continue to receive beneﬁt from
repeat treatments, as indeed was shown by our ﬁndings.
Additionally, the mean duration since the last BoNT-A
treatment was 8 months, suggesting that patients with
upper limb spasticity may not require retreatment as fre-
quently as in other conditions (such as cervical dys-
tonia). The reduction in use of other antispasmodic
medication suggests that successful treatment may pos-
sibly have allowed the reduction in or withdrawal of
other systemic agents. Many patients were receiving
other concomitant therapies at the time of their injec-
tion (eg, therapy, splinting home exercise, etc). It is pos-
sible that these interventions play a role in reducing the
frequency of BoNT-A injections, but insufﬁcient detail
regarding the frequency, duration and content of ther-
apies was collected in this study to examine this possibil-
ity in great detail. Further longitudinal studies with a
Table 4 Concomitant treatments at baseline and follow-
up
n (%) Baseline Visit 2
Physiotherapy
1–4 sessions 33 (11.7%)
5–10 sessions 50 (17.8%)
11–20 sessions 74 (26.3%)
>20 sessions 120 (42.7%)
Unknown 4 (1.4%)
Occupational therapy
1–4 sessions 34 (18.9%)
5–10 sessions 33 (18.3%)
11–20 sessions 46 (25.6%)
>20 sessions 63 (35.0%)
Unknown 4 (2.2%)
Splinting 188 (41.2%) 148 (32.5%)
Orthotics 114 (25.0%) 92 (20.2%)
Exercise 393 (86.2%) 360 (78.9%)
Passive stretching 423 (92.8%) 410 (89.9%)
Functional electrical stimulation 83 (18.2%) 58 (12.7%)
Positioning 266 (58.3%) 237 (52.0%)
Oral antispastic medication 210 (46.1%) 130 (28.5%)
No concomitant treatment 3 (0.7%) 12 (2.6%)
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systematic recording of concomitant interventions are
needed to conﬁrm these observations and to ‘open the
black box’ of a holistic approach to spasticity
management.
The authors recognise a number of limitations to this
study:
▸ Although there was a wide geographical distribution
of centres across three continents, the numerical rep-
resentation in each region was by no means represen-
tative. The recruitment of just 5–12 patients/site may
have been insufﬁcient to ensure adequate representa-
tion of practice in each centre, especially given the
wide diversity of patients and goals for treatment.
▸ The relatively low frequency of reported impairments in
cognitive and communicative function suggests either
that there is selection bias (patients with these problems
are less likely to be referred for treatment) or that there
is under-reporting (clinicians focused on treating spasti-
city are not good at identifying associated impairments
which may potentially impact on outcome).
▸ For pragmatic reasons, change on standardised
outcome measures was recorded only subjectively on
a standard scale of −2 to +2 and should therefore be
interpreted with caution.
▸ The study was not sufﬁciently powered to perform a
detailed investigation of prognostic factors for
Table 5 Primary and secondary goal areas
Goal area
Primary goals by area (n=456) Secondary goals by area (n=471)
Goal set
n (%)
Goal achieved
n (%)
(95% CI)
Partially
achieved
n (%)
Goal set
n (%)
Goal achieved
n (%)
(95% CI)
Partially
achieved
n (%)
Pain 61 (13.4) 51 (83.6)
(71.9 to 91.8)
10 (16.4) 84 (17.8) 70 (83.3)
(73.6 to 90.6)
6 (7.1)
Passive function
(ease of care)
132 (29.0) 113 (85.6)
(78.4 to 91.1)
11 (8.3) 109 (23.1) 84 (77.1)
(68.0 to 84.6)
15 (13.9)
Active function
(active use of limb)
104 (22.8) 75 (72.1)
(62.5 to 80.5)
13 (12.5) 78 (16.5) 47 (60.3)
(48.5 to 71.2)
18 (23.1)
Mobility
(balance, gait)
10 (2.2) 7 (70.0)
(34.8 to 93.3)
3 (30.0) 19 (4.0) 14 (73.7)
(48.8 to 90.9)
2 (10.5)
Involuntary movement
(associated reaction)
41 (9.0) 32 (78.0)
(62.4 to 89.4)
5 (12.2) 56 (11.9) 45 (80.4)
(67.6 to 89.8)
6 (10.7)
Impairment
(eg, range of movement)
105 (23.0) 82 (78.1)
(69.0 to 85.6)
11 (10.5) 117 (24.8) 91 (77.8)
(69.2 to 84.9)
13 (11.2)
Other 3 (0.7) 3 (100)
(29.2 to 100)
0 5 (1.1) 3 (60.0)
(14.7 to 94.7)
2 (40.0)
Total 456 363 (79.6)
(75.6 to 83.2)
53 (11.6) 468 354 (75.6)
(71.2 to 79.2)
52 (11.1)
Table 6 Standardised measures to assess upper limb spasticity at baseline
Standardised measure
Recorded at baseline Recorded at follow-up
No. showing
change
Correlation
with GAS
T-Score
n (%)* n (%)* n (%) r p value
Impairment
Tardieu 77 (16.9) 62 (13.6) 56 (90.3) 0.43 <0.001
Active range of motion 256 (56.1) 231 (50.7) 137 (59.3) 0.41 <0.001
Passive range of motion 248 (54.4) 249 (54.6) 172 (69.1) 0.43 <0.001
Associated Reaction Rating Scale23 24 (5.3) 26 (5.7) 14 (53.8) 0.76 <0.001
Symptoms/carer report
Visual Analogue Scale† 157 (34.4) 139 (30.5) 109 (78.4) 0.46 <0.001
Function
Leeds Adult Spasticity Impact Scale3 6 (1.3)‡ 5 (1.1)‡ — —
Arm Activity Scale24 27 (5.9) 27 (5.9) 14 (51.9) 0.63 <0.001
*Percentage of efficacy population.
†Parameters measured with VAS were not specified.
‡Numbers too small to compute.
GAS, goal attainment scaling.
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outcome, but it has given some preliminary insights
into potential prognostic factors within the baseline
data set.
Despite these limitations, the study provides useful
information about the way BoNT-A is used in clinical
practice around the world, and demonstrates that its
effectiveness in the management of poststroke spasticity
can be documented using individual person-centred
goals. More importantly, a large majority of the patients
achieved their treatment goals, mainly in terms of
passive and active functions, demonstrating that BoNT-A
injections contribute to an improvement in the daily life
of the patients beyond improvement of tone or spasticity.
Further secondary analyses will be presented separately
to explore the impact of different treatment strategies
including injection technique, early versus late treat-
ment and the role of concomitant therapies. Further
reﬁnement of the tools and data set are now in train to
produce a concise Upper Limb Spasticity Index that
combines GAS with selected standardised measures tar-
geted on the key goals for intervention (including the
GAS evaluation of outcome in upper-limb spasticity
(GAS-EOUS) tool).27 Tools have also been developed
for recording systematically the nature and content of
any concomitant treatments provided in routine clinical
practice. These tools will be used in the next phase of
the ULIS programme (ULIS-III) to expand the cohort
and to capture the beneﬁts of integrated spasticity man-
agement in a fully generalisable sample recorded longi-
tudinally over several cycles of BoNT-A treatment.
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